McKesson's Executive Pay Tied to Long-Term Equity Incentives
Ticker: MCK · Form: DEF 14A · Filed: Jun 20, 2025 · CIK: 927653
| Field | Detail |
|---|---|
| Company | Mckesson CORP (MCK) |
| Form Type | DEF 14A |
| Filed Date | Jun 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, DEF 14A, Equity Awards, Corporate Governance, Wholesale Drugs, SEC Filing, McKesson
Related Tickers: MCK, CAH, ABC
TL;DR
**McKesson's executive compensation is heavily weighted towards equity, signaling a long-term play for shareholder value.**
AI Summary
McKesson Corp's DEF 14A filing for the fiscal year ended March 31, 2025, highlights executive compensation and governance matters. While specific revenue and net income figures are not detailed in the provided excerpt, the filing indicates a focus on equity awards for both named executive officers (PEO) and other non-PEO executives. For the period April 1, 2024, to March 31, 2025, equity awards granted to PEOs are reported, alongside adjustments excluding values already reported in the summary compensation table. Similar equity award data is provided for the preceding four fiscal years, demonstrating a consistent compensation structure. The filing also details the year-end fair value of outstanding and unvested equity awards for PEOs, changes in fair value, and the fair value of awards vested during the covered year. This suggests a strategic outlook tied to long-term equity incentives, aligning executive interests with shareholder value, though specific business changes or risks are not explicitly quantified in this excerpt.
Why It Matters
This DEF 14A filing is crucial for investors as it details McKesson's executive compensation structure, particularly the significant role of equity awards. Understanding how executives are incentivized provides insight into the company's strategic direction and commitment to shareholder value. A compensation model heavily reliant on equity, as indicated, suggests a long-term focus, which can impact employee retention and motivation. In the highly competitive wholesale drug and sundries market, attracting and retaining top talent through competitive compensation is vital for McKesson to maintain its market position against rivals like Cardinal Health and AmerisourceBergen.
Risk Assessment
Risk Level: low — The filing primarily concerns executive compensation and governance, not operational or financial risks. The consistent reporting of equity awards across multiple years (2020-2025) suggests a stable and transparent compensation framework, indicating low immediate risk from this specific filing content.
Analyst Insight
Investors should analyze the full DEF 14A to understand the performance metrics tied to these equity awards. This will reveal the specific goals McKesson's executives are incentivized to achieve, providing a clearer picture of the company's strategic priorities and potential for future growth.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| full name | exact role | $X |
Key Numbers
- 2025-03-31 — Fiscal Year End (Conformed period of report for the DEF 14A filing)
- 2025-06-20 — Filed As Of Date (Date the DEF 14A was officially filed with the SEC)
- 1934 Act — SEC Act (The Securities Exchange Act under which the DEF 14A is filed)
- 001-13252 — SEC File Number (McKesson Corp's SEC file number)
- 5122 — SIC Code (Standard Industrial Classification for Wholesale-Drugs Proprietaries & Druggists' Sundries)
Key Players & Entities
- MCKESSON CORP (company) — filer of DEF 14A
- 0000927653 (regulator) — Central Index Key (CIK) for McKesson Corp
- Irving, TX (location) — business address of McKesson Corp
- Delaware (location) — state of incorporation for McKesson Corp
- Cardinal Health (company) — competitor in wholesale drug market
- AmerisourceBergen (company) — competitor in wholesale drug market
FAQ
What is McKesson's fiscal year end according to the DEF 14A?
McKesson Corp's fiscal year end, as reported in the DEF 14A filing, is March 31, 2025. This date defines the period covered by the compensation and governance disclosures.
When was McKesson's DEF 14A filing submitted to the SEC?
The DEF 14A filing for McKesson Corp was filed with the SEC on June 20, 2025. This is the official date the document became publicly available.
What type of compensation is emphasized for McKesson's executives in this filing?
The filing emphasizes equity awards for McKesson's named executive officers (PEO) and other non-PEO executives. This indicates a significant portion of their compensation is tied to company stock performance.
What is the primary business classification for McKesson Corp?
McKesson Corp's primary business classification is 'Wholesale-Drugs Proprietaries & Druggists' Sundries' under SIC code 5122. This defines its core operations in the healthcare supply chain.
How many public documents are associated with this McKesson DEF 14A filing?
There are 182 public documents associated with this specific McKesson DEF 14A filing. This number indicates the comprehensive nature of the submission.
What is the significance of equity awards for McKesson's PEOs?
Equity awards for McKesson's PEOs are significant because they align executive interests with long-term shareholder value. The filing details the fair value of these awards, including outstanding, unvested, and vested portions.
Where is McKesson Corp's business address located?
McKesson Corp's business address is 6555 State Highway 161, Irving, TX 75039. This is the company's headquarters.
Under which SEC Act was McKesson's DEF 14A filed?
McKesson's DEF 14A was filed under the 1934 Act, which governs the reporting requirements for publicly traded companies.
Does the McKesson DEF 14A provide specific revenue figures?
No, the provided excerpt of the McKesson DEF 14A filing does not detail specific revenue or net income figures. It primarily focuses on executive compensation and governance disclosures.
What is McKesson's state of incorporation?
McKesson Corp is incorporated in the state of Delaware. This is a common practice for many large U.S. corporations.
Industry Context
McKesson Corp operates in the wholesale drug and pharmaceutical sundries sector, a critical part of the healthcare supply chain. This industry is characterized by significant regulatory oversight, complex logistics, and intense competition from other major distributors and increasingly, from manufacturers selling directly to providers.
Regulatory Implications
As a major pharmaceutical distributor, McKesson is subject to stringent regulations concerning drug handling, distribution, and pricing. Changes in healthcare policy, drug pricing reforms, and compliance with controlled substance regulations are ongoing areas of focus and potential risk.
What Investors Should Do
- Review equity award details for PEOs and Non-PEO NEOs.
- Analyze the fair value changes of outstanding and unvested equity awards.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the DEF 14A filing.
- 2025-06-20: Filed As Of Date — Indicates the date the DEF 14A was officially filed with the SEC.
Glossary
- DEF 14A
- A proxy statement filed by public companies with the SEC detailing information about executive compensation, board of directors, and other corporate governance matters. (This document provides the core information regarding McKesson Corp's executive compensation and governance practices for the fiscal year.)
- PEO
- Principal Executive Officer, typically the CEO of the company. (The filing specifically details equity awards granted to the PEO, indicating their importance in the compensation structure.)
- Non-PEO NEO
- Non-Principal Executive Officer Named Executive Officer. These are other top executives of the company besides the PEO. (Equity award information is also provided for this group, showing a broader application of long-term incentives.)
- Equity Awards
- Awards granted to employees in the form of company stock, stock options, or other equity-based instruments. (The filing heavily emphasizes equity awards, suggesting a compensation strategy focused on aligning executive interests with long-term shareholder value.)
- Fair Value
- The estimated market price of an asset or liability, often determined using valuation models. (The filing reports the year-end fair value of outstanding and unvested equity awards, as well as changes in fair value and vested awards, crucial for understanding the total compensation value.)
- Summary Compensation Table
- A table in proxy statements that summarizes the total compensation for the company's top executives over the last three fiscal years. (The filing references adjustments excluding values already reported in this table, indicating a detailed breakdown of compensation components.)
Year-Over-Year Comparison
The provided excerpt focuses on executive compensation and equity awards for the fiscal year ending March 31, 2025, and compares it to previous years. While specific financial metrics like revenue and net income are not detailed here, the consistent reporting of equity awards suggests a stable compensation philosophy aimed at long-term executive alignment with shareholder interests.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 20, 2025 regarding MCKESSON CORP (MCK).